SCHEMBL5565698

SCHEMBL5565698

CCCC(=O)c1ccc(C)c(C)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B3 P37058 2/20 0.57
HPGD P15428 5/20 0.53
SMN1; SMN2 Q16637 2/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
TAS1R3 Q7RTX0 1/20 0.49
TAS1R1 Q7RTX1 1/20 0.49
HTT P42858 2/20 0.48
CES2 O00748 1/20 0.48
CES1 P23141 1/20 0.48
MAPK1 P28482 1/20 0.48
MAPT P10636 4/20 0.47
LMNA P02545 2/20 0.47
GAA P10253 1/20 0.47
ALDH1A1 P00352 5/20 0.46
RAB9A P51151 3/20 0.46
NPC1 O15118 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
STS P08842 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5565263 0.87 HSD17B3 (0.61) HSD17B3MEN1KMT2ATAS1R3TAS1R1
SCHEMBL6812061 0.85 HSD17B3 (0.58) HSD17B3HPGDSMN1; SMN2L3MBTL1MEN1
SCHEMBL7701905 0.83 ALDH1A1 (0.53) HPGDSMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL24403947 0.83 MAPT (0.61) HSD17B3HPGDSMN1; SMN2L3MBTL1MEN1
SCHEMBL5461438 0.83 MAPT (0.57) HSD17B3HPGDSMN1; SMN2L3MBTL1MEN1
SCHEMBL27652151 0.83 HPGD (0.58) HSD17B3HPGDSMN1; SMN2L3MBTL1MEN1
SCHEMBL5081102 0.82 KMT2A (0.63) HPGDSMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL5254127 0.82 KMT2A (0.47) HPGDSMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL21852336 0.82 MEN1 (0.47) HPGDSMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL29816406 0.82 MEN1 (0.47) HPGDSMN1; SMN2L3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1745004-B1 ARYL KETONE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECH INC (US) 2016-05-18 EP disclosed
US-8697737-B2 Raf modulators and methods of use EXELIXIS, INC. (US) 2014-04-15 US disclosed
US-20110071145-A1 Raf Modulators And Methods Of Use EXELIXIS, INC. (US) 2011-03-24 US disclosed
US-7846959-B2 Raf modulators and methods of use EXELIXIS, INC. (US) 2010-12-07 US disclosed
US-20080009488-A1 Raf Modulators and Methods of Use EXELIXIS, INC. (US) 2008-01-10 US disclosed
EP-1745004-A4 ARYL KETONE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECH INC (US) 2007-05-09 EP disclosed
CN-1934088-A As 5-HT2c6-substituted 2,3,4, 5-tetrahydro-1H-benzo [ d ] receptor agonists]Aza * LILLY CO ELI (US) 2007-03-21 CN disclosed
EP-1745004-A2 ARYL KETONE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS Emisphere Technologies, Inc. (US) 2007-01-24 EP disclosed
WO-2005117854-A2 ARYL KETONE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2005-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009488-A1 Raf Modulators and Methods of Use BRAF, RAF1, ARAF HSD17B3 3630/4885HPGD 2131/4885SMN1; SMN2 4354/4885
US-20110071145-A1 Raf Modulators And Methods Of Use BRAF, RAF1, ARAF HSD17B3 3202/4885HPGD 1817/4885SMN1; SMN2 4555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.